Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatitis C virus (HCV) genotype 1 infection (confirmed at screening).~* HCV ribonucleic acid (RNA) greater than 10,000 IU/mL at screening~* Treatment-experienced participants must have at least 1 documented previous course of interferon-based regimen with or without ribavirin~* Participants must have an hepatic imaging procedure (ultrasound, computerized tomography scan or magnetic resonance imaging scan) within 6 months prior to the screening visit (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma~* Participant must be willing and able to comply with the protocol requirements~* Participants with liver cirrhosis~Exclusion Criteria:~* Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)~* Infection/co-infection with HCV non-genotype 1~* Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)~* Co-infection with hepatitis B virus (hepatitis B-surface-antigen positive)~* Previously been treated with any direct acting anti-HCV agent (approved or investigational) for chronic HCV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Simeprevir/Sofosbuvir) (Type: EXPERIMENTAL): 100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).